| Patient | Zelda Fitzgerald |
|---|---|
| Date of birth | 1900-07-24 |
| Identifiers | MRN HR-ET004-SYN-TD; SSN (made up) 000-04-8712 |
| Document date | 1930-05-18 |
| Author | Margot Ellery, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-week review, seen the same day by psychiatry with the coordinated specialty care team. [S]
Ms. Fitzgerald returns one week after her first visit and is seen by Dr. Langford of the coordinated specialty care team on the same day. She takes risperidone 2 mg every night. She sleeps nine or ten hours and feels heavy and slow in the mornings. She has had no voices, no sense of being watched, and no racing thoughts. Her mood is still low but less tearful, and she has begun writing again for an hour a day. Her periods have still not returned; she has had no breast discharge. She is eating three small meals and has not danced. She is worried that medicines will make her gain weight and end her dancing. She has had no thoughts of suicide or self-harm. [S]
| Element | Detail |
|---|---|
| Risperidone | 2 mg at bedtime, every dose taken |
| Psychotic and manic symptoms | None |
| Mood | Low but improving; PHQ-9 9; item 9 scored 0 |
| Sleep | Nine or ten hours; slow in the mornings |
| Periods | Still absent; no breast discharge |
| Concern | Weight gain and her dancing |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the mornings; weight stable |
| Genitourinary | Positive | No periods for about five months; no pelvic pain |
| Endocrine | Negative | No breast discharge; no heat or cold intolerance |
| Neurological | Negative | No restlessness, stiffness, or tremor |
| Psychiatric | Positive | Low mood, improving; no voices, racing thoughts, or thoughts of suicide or self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Risperidone 2 mg oral tablet, one tablet by mouth at bedtime (started in hospital) | One tablet by mouth at bedtime | Oral route | 1930-04-20 to 1930-06-08 | completed | S |
| Lithium carbonate 300 mg oral capsule, one capsule by mouth twice daily | One capsule by mouth twice daily | Oral route | 1930-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1930-05-18 | Body height | 165 | cm | S |
| 1930-05-18 | Body weight | 51 | kg | S |
| 1930-05-18 | Body mass index (BMI) [Ratio] | 18.7 | kg/m2 | S |
| 1930-05-18 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1930-05-18 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1930-05-18 | Heart rate | 76 | /min | S |
| 1930-05-18 | Respiratory rate | 14 | /min | S |
| 1930-05-18 | Body temperature | 36.5 | Cel | S |
| 1930-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1930-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S |
Vital signs recorded on 1930-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Slim and well; weight 51.0 kg, BMI 18.7; waist 66 cm; blood pressure 106/66, pulse 76 |
| Neurological | No akathisia, rigidity, tremor, or abnormal movements; AIMS score 0 |
| Psychiatric | Quiet, reactive affect; organized; no psychotic or manic features; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First episode of psychosis with marked mood symptoms: about three weeks of little sleep, rapid speech, racing thoughts, grandiose plans and very long training days, then a voice commenting on her dancing and a belief that she was being watched and tested; tearful low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, schizoaffective disorder (bipolar type), and schizophreniform disorder or schizophrenia, depending on whether the psychosis ever occurred apart from the mood symptoms. Synthetic modern episode linked to her documented first hospitalization | active | provisional | F29 | S — Synthetic modern coding of the documented first breakdown. Unspecified psychosis is coded until the course shows how the psychosis relates to the mood symptoms; superseded at the three-month visit. |
| Secondary amenorrhea: no periods for about four months before admission, during very heavy dance training at a low weight (BMI 18.7), with prolactin raised on risperidone; pregnancy test negative | active | confirmed | N91.1 | S — Synthetic presenting finding linked to her documented training; resolved when her periods returned. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Risperidone 2 mg; full adherence; no psychotic or manic symptoms |
| Survey | Manic, depressive, and psychotic symptoms, and early warning signs | Every visit | Completed today | No manic or psychotic symptoms; depressive phase easing |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | Morning sedation; no akathisia or parkinsonism |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Baseline, then every 6 months | Completed today | Baseline AIMS score 0, done with the consultation |
| Examination | Weight and BMI | Every visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 51.0 kg (BMI 18.7); waist 66 cm |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 106/66 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Glucose 84 mg/dL and A1c 5.0% at intake; next at 12 weeks to 4 months |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at intake; next at 12 weeks to 4 months |
| Laboratory | Prolactin | When there are symptoms of high prolactin, such as missed periods | Up to date | 62 ng/mL at intake with absent periods; repeat at the next check |
| Laboratory | Electrocardiogram | Before lithium if over 40 or with heart disease; before an antipsychotic with cardiac risk factors | Not indicated | Age 29, no heart disease, fainting, or family history of sudden death |
| Laboratory | Creatinine and eGFR on lithium | Baseline, every 2 to 3 months for 6 months, then every 6 to 12 months | Up to date | Baseline creatinine 0.72 mg/dL, eGFR 116, a week ago |
| Laboratory | TSH on lithium | Baseline, once or twice in the first 6 months, then every 6 to 12 months | Up to date | Baseline TSH 2.1 mIU/L a week ago |
| Laboratory | Calcium on lithium | Baseline, then yearly | Up to date | Baseline calcium 9.4 mg/dL a week ago |
| Laboratory | Lithium level (12-hour trough) | 5 to 7 days after starting and after any change until stable, then every 3 to 6 months | Due | Lithium started today; level ordered for 5 to 7 days from now |
| Medication safety | Lithium side effects and sick-day rules | At the start and every visit | Completed today | Tremor, thirst, nausea and signs of toxicity explained; take with food; keep drinking normally; no anti-inflammatory painkillers |
| Medication safety | Pregnancy prevention on lithium; valproate avoided | Before starting and at each visit until a reliable method is in place | Completed today | Urine pregnancy test negative today; valproate avoided; the small risk of heart defects with lithium early in pregnancy explained; condoms reliably for now |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 9, from 11; item 9 scored 0 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; no firearm access; lithium dispensed two weeks at a time |
| Self-management | Sleep | Every visit | Completed today | Nine or ten hours on risperidone; regular times agreed |
| Self-management | Eating, exercise, and periods | Every visit while periods are absent or weight is low | Completed today | SCOFF 1 of 5 a week ago; three small meals; not dancing; periods absent; dietitian arranged |
| Referral | Psychiatry consultation | At the start of treatment for a first episode | Completed today | Seen by Dr. Langford today |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Enrolled today |
Goal progress:
Guideline basis: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Lithium level in 5 to 7 days at the laboratory. Visit in three weeks with lithium level, creatinine, electrolytes, prolactin, and the PHQ-9. Care coordinator weekly; dietitian next week. Next scheduled visit 1930-06-08: lithium level after the sick visit, prolactin, and the antipsychotic plan. [S]